Cancer Care Gets Cheaper: NPPA Caps Trade Margins on 137 Drugs
NPPA implements a 30% trade margin cap on 137 anti-cancer drugs, slashing prices and saving consumers over ₹3,500 crore annually.
In a massive move to make life-saving treatment more affordable, the National Pharmaceutical Pricing Authority (NPPA) has implemented strict trade margin caps on 137 non-scheduled anti-cancer drugs price cut measures. Effective from November 9, 2026, this regulatory intervention aims to slash the financial burden on patients battling cancer by limiting the profit margins earned by distributors and retailers.
The 30 Percent Limit: How it Works
Operating under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilisers, the NPPA has mandated a trade margin limit of 30 percent on the Maximum Retail Price (MRP), excluding GST. This decision was powered by Paragraph 19 of the Drugs (Prices Control) Order, 2013, and follows specific recommendations provided by an Expert Committee from the Directorate General of Health Services (DGHS) on October 17, 2026.
Massive Price Drops and Consumer Savings
The impact of this policy is already visible in the data submitted by the pharmaceutical industry. As of November 8, 2026, 85 pharmaceutical companies have provided revised MRPs for 1,364 different anti-cancer formulations, which cover 121 individual drugs.
The scale of the price reductions is staggering:
- Widespread Cuts: 679 different brands have already implemented price reductions of more than 50 percent.
- Maximum Drop: Some formulations have seen a price plunge as high as 96.45 percent.
- Total Savings: The Ministry estimates that these price revisions will save consumers approximately ₹3,540.38 crore annually.
Future-Proofing and Market Reach
The NPPA isn't just looking at current inventory. The authority has stipulated that this trade margin cap will also extend to 10 to 15 anti-cancer drugs that are yet to be launched in the Indian market, ensuring that new treatments enter the country at fair price points.
Strict Enforcement and Compliance
To ensure that these savings actually reach the patient, the government has laid down strict mandates for the supply chain:
- No Overcharging: Hospitals, pharmacies, and chemists are strictly prohibited from selling these drugs above the revised MRP.
- Transparency: Updated price lists must be prominently displayed both on the premises of the pharmacy/hospital and on their digital platforms.
- Monitoring: State Drug Controllers have been officially directed to oversee the enforcement of these rules across their respective regions.
How Patients Can Verify Prices and Report Fraud
The government has provided multiple tools for consumers to ensure they are not being cheated:
- Verification: Current and revised pricing can be checked via the Pharma Sahi Daam mobile application or the official NPPA website.
- Complaints: Any instance of overcharging can be reported through the Pharma Jan Samadhan portal.
- Helpline: A dedicated helpline has been set up at 1800-111-255 for immediate assistance.